Breaking News
Specific lots of intravenous immune globulin (IVIG) and subcutaneous IG (SCIG) have been voluntarily withdrawn by the manufacturers due to a higher rate of allergic/hypersensitivity type reactions, some of which were considered medically significant.
Grifols announced positive results from its Phase II/III clinical trial evaluating the efficacy and safety of Flebogamma 5% DIF (intravenous immune globulin [IVIG]) to treat patients with post-polio syndrome, which demonstrated a significant improvement in distance walked compared to placebo.
A new study published in the journal Nature found that a personalized vaccine, named autogene cevumeran, is showing promising results for treating pancreatic cancer, one of the deadliest malignancies.
BioTrending
- By Trudie Mitschang
As a patient-driven priority, personalized healthcare is poised to become a permanent fixture in the public health landscape.
- By Keith Berman, MPH, MBA
A number of promising new agents in the R&D pipeline are likely to be approved in the very near future, expanding an already impressive range of treatment options — while further increasing the complexity of the HAE management decision process.
- By Lee Warren
Overseeing a loved one's healthcare is stressful, especially when at a distance. These innovative strategies can help.
- By Rachel Maier, MS
With its lower costs and patient preference, HaH is poised to alleviate some of the problems hospitals face, but there are obstacles to overcome before it becomes a mainstay program.
BSTQ Podcast: Marketplace News & Insights
Awards
BSTQ is an Industry Award-Winning Journal
Since its debut in 2009, BioSupply Trends Quarterly’s articles have been recognized by some of the industry’s most prominent organizations, earning platinum and gold awards.
